Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
11. Mai 2021 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
08. Oktober 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), announced today a new marketing and public awareness campaign around their FDA...
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
09. September 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an additional opportunity to view a live webinar presentation...
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
20. August 2020 14:51 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended...
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
27. Juli 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir...
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
21. Juli 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating...
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
15. Juni 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
01. Juni 2020 10:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement...
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
26. Mai 2020 08:18 ET
|
Endonovo Therapeutics, Inc.
Agreement Provides Flexible Access to Funding at a Lower Cost of Capital Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company")...
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
04. Mai 2020 08:15 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...